Understanding the Results

Knowing Your Tumor Class Can Be Extremely Helpful to You and Your Doctor

DecisionDx®-UM measures the activity of 15 specific genes within your eye tumor to determine the likelihood of it spreading from the eye. The test identifies your prognosis as either Class 1A, Class 1B or Class 2, which provides the risk of your tumor spreading (metastasis) over five years, the period for which data has been collected.

This information can be extremely helpful to you and your doctor in planning your follow-up care. There are considerations about the kind and frequency of monitoring you will need, and whether you would be a candidate for certain treatments or even clinical trials as they become available.

Below are the potential test results, and the considerations for each:

Class 1A

Class 1A

These patients are at a low risk of metastasis, with just a 2% chance of the eye cancer spreading over the next five years. Your doctor may recommend a less frequent monitoring program to screen for metastasis, which might include bloodwork, office visit(s) and/or imaging such as X-ray, ultrasound, CT/PET or MRI.

Class 1B

Class 1B

These patients have an intermediate risk of metastasis, or 21% over the next five years. To be on the safe side, your doctor may choose to monitor you more closely.

Class 2

Class 2

These patients are at high risk, with 72% risk of metastasis over the next five years.

If you have a Class 2 tumor, your doctor may recommend a high intensity program to monitor you for evidence of metastasis. This might include quarterly MRI or CT scans, along with quarterly liver function tests. Your doctor may also recommend referral to a medical oncologist for preventive treatment, and to review clinical trial opportunities. Results from genomic testing such as DecisionDx-UM will help determine whether or not you might qualify for such trials as they become available.

While the DecisionDx-UM test cannot, at this point, guide your doctor toward a specific therapy, a study published in Clinical Ophthalmology, which involved doctor surveys and medical chart review of Medicare-treated patients, showed that molecular testing such as the GEP test has a significant impact on the management of uveal melanoma. Not only are most ophthalmologists treating uveal melanoma using molecular testing, but they are also more likely to increase frequency of disease monitoring or recommend clinical trials for those patients whose test results showed they were at high risk of metastasis. This was confirmed in two recent prospective studies published in Journal of Oncology and Melanoma Management.

Decisions about your surveillance, treatment and other follow-up plans should be made by you and your doctors.

Learn How DecisionDx®-UM
Can Help Determine
Your Personalized Risk


Timing Is Critical – Talk With Your Doctor

Our Discussion Guide Will Help Determine If DecisionDx-UM Is Right for You

Hear From Other Patients

Learn How DecisionDx-UM Has Made a Significant Impact on the Lives of Other Uveal Melanoma Patients.


What’s Next?

Where to Get Tested

How Do You Get a
DecisionDx-UM Test?